Yunding New Shine plans to acquire Heisen Pharmaceuticals Singapore company for $250 million, with last year's revenue increasing by 142%.

NightAirdropper · 2026-04-12T20:25:25+00:00

Genting New Dawn recently announced the acquisition of Haisen Biopharmaceutical (Singapore) Limited for $250 million, with the transaction to be paid in three installments. After the acquisition, Haisen Biopharmaceutical will become a new subsidiary of Genting. In 2025, Genting New Dawn's revenue surged by 142%, marking its first profit turnaround.

NightAirdropper

2026-04-12 20:25:25

Abstract generation in progress

Sino Finance, Yan Minghui On April 8, Genting New Dawn (01952.HK) announced that its wholly owned subsidiary in Singapore, EverSea Medicines (Singapore) Pte. Ltd., has signed an equity purchase agreement with Haisen Biopharmaceuticals (Asia) Limited to acquire all the equity interests in its wholly owned subsidiary, Haisen Biopharmaceuticals (Singapore) Limited. The total consideration for this transaction is USD 250 million (approximately RMB 1.722 billion). The payment will be made in three installments, subject to the completion of all relevant conditions precedent for each installment, or waiver by the buyer.

After completion of the closing, Haisen Biopharmaceuticals (Singapore) Limited will become an indirectly wholly owned subsidiary of Genting New Dawn, and its financial performance will be consolidated into the company’s financial statements.

According to Genting New Dawn’s disclosed full-year performance report for 2025, the company’s revenue for the full year increased significantly by 142% year over year to RMB 1.707 billion. For the first time under non-IFRS (International Financial Reporting Standards), it achieved a turnaround from loss to profit, recording a profit of RMB 187 million. Under IFRS, the loss was also substantially narrowed by 71%, and operating cash flow successfully turned positive.

The chairman of the board is Wu Yifang, who was formerly chairman of Fosun Pharma and has more than 35 years of experience in the biopharmaceutical industry.

Related company: Genting New Dawn HK01952

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes